Its different now, Brooks told Us Weekly after the show aired
GLP-1: slows stomach emptying, reduces glucagon and increases satiety (fullness)
Vear A, Heneka MT, Clemmensen C (2025) Incretin-based therapeutics for the treatment of neurodegenerative diseases
These trials demonstrated its efficacy and safety in Type 2 diabetes with or without other anti-diabetic agents [42, 44,45,46,47]
Their effectiveness in the long run requires their combination with the following: Healthy eating habits Regular physical activity Ongoing medical supervision The weight loss from GLP-1 drugs must be slow and sustainable rather than quick and erratic
Proper diagnosis ensures appropriate treatment